{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:16:41Z","timestamp":1757618201346,"version":"3.44.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332023058","2023-I2M-C&T-B-108"],"award-info":[{"award-number":["3332023058","2023-I2M-C&T-B-108"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Natural Science Foundation","doi-asserted-by":"crossref","award":["23JCZXJC00040","23JCZXJC00220"],"award-info":[{"award-number":["23JCZXJC00040","23JCZXJC00220"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170217","82070192"],"award-info":[{"award-number":["82170217","82070192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology of China","award":["2021YFA1101603"],"award-info":[{"award-number":["2021YFA1101603"]}]},{"name":"Key Project of Tianjin Natural Science Foundation","award":["20JCZDJC00410"],"award-info":[{"award-number":["20JCZDJC00410"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-073"],"award-info":[{"award-number":["2021-I2M-1-073"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2508902"],"award-info":[{"award-number":["2023YFC2508902"]}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["22HHXBSS00034"],"award-info":[{"award-number":["22HHXBSS00034"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["023ZD0502400"],"award-info":[{"award-number":["023ZD0502400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06407-w","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T21:13:14Z","timestamp":1749244394000},"page":"3459-3468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China"],"prefix":"10.1007","volume":"104","author":[{"given":"Hongye","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"11","key":"6407_CR1","first-page":"3055","volume":"12","author":"J Liu","year":"2011","unstructured":"Liu J, Song B, Fan T, Huang C, Xie C, Li J et al (2011) Pathological and clinical characteristics of 1,248 non-Hodgkin\u2019s lymphomas from a regional cancer hospital in Shandong, China. Asian Pac J Cancer Prev 12(11):3055\u20133061","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"6407_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12185-008-0132-1","volume":"88","author":"SA Gross","year":"2008","unstructured":"Gross SA, Zhu X, Bao L, Ryder J, Le A, Chen Y et al (2008) A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. Int J Hematol 88(2):165\u2013173. https:\/\/doi.org\/10.1007\/s12185-008-0132-1","journal-title":"Int J Hematol"},{"issue":"2","key":"6407_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3904\/kjim.2009.24.2.128","volume":"24","author":"OB Ko","year":"2009","unstructured":"Ko OB, Lee DH, Kim SW, Lee JS, Kim S, Huh J, Suh C (2009) Clinicopathologic characteristics of T-cell non-Hodgkin\u2019s lymphoma: a single institution experience. Korean J Intern Med 24(2):128\u2013134. https:\/\/doi.org\/10.3904\/kjim.2009.24.2.128","journal-title":"Korean J Intern Med"},{"issue":"9","key":"6407_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1440-1827.2000.01108.x","volume":"50","author":"The world health organization classification of malignant lymphomas in","year":"2000","unstructured":"The world health organization classification of malignant lymphomas in (2000) Japan: incidence of recently recognized entities. Lymphoma study group of Japanese pathologists. Pathol Int 50(9):696\u2013702. https:\/\/doi.org\/10.1046\/j.1440-1827.2000.01108.x","journal-title":"Pathol Int"},{"issue":"1","key":"6407_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106\u2013113. https:\/\/doi.org\/10.1200\/jco.2008.17.4870","journal-title":"J Clin Oncol"},{"issue":"25","key":"6407_CR6","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al (2012) Up-Front autologous Stem-Cell transplantation in peripheral T-Cell lymphoma: NLG-T-01. J Clin Oncol 30(25):3093\u20133099. https:\/\/doi.org\/10.1200\/JCO.2011.40.2719","journal-title":"J Clin Oncol"},{"issue":"7","key":"6407_CR7","doi-asserted-by":"publisher","first-page":"10225","DOI":"10.18632\/aging.202782","volume":"13","author":"H Gao","year":"2021","unstructured":"Gao H, Ji X, Liu X, Mi L, Liu W, Wang X et al (2021) Conditional survival and hazards of death for peripheral T-cell lymphomas. Aging 13(7):10225\u201310239. https:\/\/doi.org\/10.18632\/aging.202782","journal-title":"Aging"},{"issue":"7","key":"6407_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.24372","volume":"91","author":"C Yam","year":"2016","unstructured":"Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J et al (2016) Autologous stem cell transplantation in first complete remission May not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol 91(7):672\u2013676. https:\/\/doi.org\/10.1002\/ajh.24372","journal-title":"Am J Hematol"},{"issue":"3","key":"6407_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E et al (2018) Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 29(3):715\u2013723. https:\/\/doi.org\/10.1093\/annonc\/mdx787","journal-title":"Ann Oncol"},{"issue":"4","key":"6407_CR10","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/bjh.19317","volume":"204","author":"P Yang","year":"2024","unstructured":"Yang P, Cai M, Cao Y, Fan S, Tang W, Ji M et al (2024) Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis. Br J Haematol 204(4):1414\u20131421. https:\/\/doi.org\/10.1111\/bjh.19317","journal-title":"Br J Haematol"},{"issue":"5","key":"6407_CR11","doi-asserted-by":"publisher","first-page":"e219807","DOI":"10.1001\/jamanetworkopen.2021.9807","volume":"4","author":"J Du","year":"2021","unstructured":"Du J, Yu D, Han X, Zhu L, Huang Z (2021) Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-Cell lymphoma: A systematic review and Meta-analysis. JAMA Netw Open 4(5):e219807. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.9807","journal-title":"JAMA Netw Open"},{"issue":"19","key":"6407_CR12","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood.2020008825","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G et al (2021) A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 137(19):2646\u20132656. https:\/\/doi.org\/10.1182\/blood.2020008825","journal-title":"Blood"},{"issue":"4","key":"6407_CR13","doi-asserted-by":"publisher","first-page":"100723","DOI":"10.1016\/j.adro.2021.100723","volume":"6","author":"R Pearlman","year":"2021","unstructured":"Pearlman R, Hanna R, Burmeister J, Abrams J, Dominello M (2021) Adverse effects of total body irradiation: A Two-Decade, single institution analysis. Adv Radiat Oncol 6(4):100723. https:\/\/doi.org\/10.1016\/j.adro.2021.100723","journal-title":"Adv Radiat Oncol"},{"issue":"48","key":"6407_CR14","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.3760\/cma.j.issn.0376-2491.2019.48.006","volume":"99","author":"L Wang","year":"2019","unstructured":"Wang L, Li NN, Wang Z, Wu XX, Dong YJ, Fu XR et al (2019) [Evaluation of clinical outcomes of allogeneic hematopoietic stem cell transplantation for relapsed\/refractory peripheral T-cell lymphoma with chemoresistance]. Zhonghua Yi Xue Za Zhi 99(48):3786\u20133791. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2019.48.006","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"5","key":"6407_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00277-018-3559-3","volume":"98","author":"Z Gu","year":"2019","unstructured":"Gu Z, Wang L, Wang Q, Li H, Bo J, Wang S et al (2019) Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed\/refractory peripheral T cell lymphomas. Ann Hematol 98(5):1237\u20131247. https:\/\/doi.org\/10.1007\/s00277-018-3559-3","journal-title":"Ann Hematol"},{"issue":"8","key":"6407_CR16","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","volume":"52","author":"J Zain","year":"2011","unstructured":"Zain J, Palmer JM, Delioukina M, Thomas S, Tsai N-C, Nademanee A et al (2011) Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 52(8):1463\u20131473. https:\/\/doi.org\/10.3109\/10428194.2011.574754","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"6407_CR17","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A et al (2014) Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28(9):1885\u20131891. https:\/\/doi.org\/10.1038\/leu.2014.79","journal-title":"Leukemia"},{"issue":"3","key":"6407_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al (2012) Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3):520\u2013526. https:\/\/doi.org\/10.1038\/leu.2011.240","journal-title":"Leukemia"},{"issue":"11","key":"6407_CR19","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.bbmt.2013.07.003","volume":"19","author":"A Czajczynska","year":"2013","unstructured":"Czajczynska A, G\u00fcnther A, Repp R, Humpe A, Schub N, Raff T et al (2013) Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-Cell Non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant 19(11):1632\u20131637. https:\/\/doi.org\/10.1016\/j.bbmt.2013.07.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"6407_CR20","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","volume":"22","author":"ED Jacobsen","year":"2011","unstructured":"Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC et al (2011) A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis Fungoides\/Sezary syndrome. Ann Oncol 22(7):1608\u20131613. https:\/\/doi.org\/10.1093\/annonc\/mdq698","journal-title":"Ann Oncol"},{"issue":"8","key":"6407_CR21","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.bbmt.2017.04.021","volume":"23","author":"H Huang","year":"2017","unstructured":"Huang H, Jiang Y, Wang Q, Guo L, Jin Z, Fu Z et al (2017) Outcome of allogeneic and autologous hematopoietic cell transplantation for High-Risk peripheral T cell lymphomas: A retrospective analysis from a Chinese center. Biol Blood Marrow Transplant 23(8):1393\u20131397. https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.021","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"6407_CR22","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","volume":"27","author":"C Kyriakou","year":"2009","unstructured":"Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau J-L, Kolb H-J et al (2009) Allogeneic stem cell transplantation is able to induce Long-Term remissions in angioimmunoblastic T-Cell lymphoma: A retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27(24):3951\u20133958. https:\/\/doi.org\/10.1200\/JCO.2008.20.4628","journal-title":"J Clin Oncol"},{"issue":"11","key":"6407_CR23","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3760\/cma.j.issn.0253-2727.2016.11.005","volume":"37","author":"QL Wang","year":"2016","unstructured":"Wang QL, Huang HW, Jin ZM, Tang XW, Qiu HY, Fu CC et al (2016) [Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas]. Zhonghua Xue Ye Xue Za Zhi 37(11):952\u2013956. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2016.11.005","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"14","key":"6407_CR24","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Le Gouill","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, Peffault De Latour R, Vernant J-P, Mohty M et al (2008) Graft-Versus-Lymphoma effect for aggressive T-Cell lymphomas in adults: A study by the Soci\u00e9t\u00e9 Fran\u00e7aise de greffe de Mo\u00eblle et de th\u00e9rapie cellulaire. J Clin Oncol 26(14):2264\u20132271. https:\/\/doi.org\/10.1200\/JCO.2007.14.1366","journal-title":"J Clin Oncol"},{"key":"6407_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40164-024-00557-9","volume":"13","author":"H Gao","year":"2024","unstructured":"Gao HY, Zhang ZX, Wang JL, Jia YN, Cao WB et al (2024) Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China. Exp Hematol Oncol 13:88","journal-title":"Exp Hematol Oncol"},{"issue":"20","key":"6407_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"27","key":"6407_CR27","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"6","key":"6407_CR28","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C et al (2020) Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl 55(6):1114\u20131125. https:\/\/doi.org\/10.1038\/s41409-020-0803-y","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"6407_CR29","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR et al (2018) EBMT\u2009\u2013\u2009NIH\u2009\u2013\u2009CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53(11):1401\u20131415. https:\/\/doi.org\/10.1038\/s41409-018-0204-7","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6407_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al (2015) National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl 21(3):389\u2013401e381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"6407_CR31","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474\u20132479. https:\/\/doi.org\/10.1182\/blood-2003-09-3080","journal-title":"Blood"},{"issue":"446","key":"6407_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"6407_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.exphem.2005.10.010","volume":"34","author":"EM Kang","year":"2006","unstructured":"Kang EM, Hsieh MM, Metzger M, Krouse A, Donahue RE, Sadelain M et al (2006) Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp Hematol 34(2):132\u2013139. https:\/\/doi.org\/10.1016\/j.exphem.2005.10.010","journal-title":"Exp Hematol"},{"issue":"4","key":"6407_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.1958.tb06038.x","volume":"4","author":"LA Elson","year":"1958","unstructured":"Elson LA, Galton DA, Till M (1958) The action of Chlorambucil (CB. 1348) and Busulphan (myleran) on the Haemopoietic organs of the rat. Br J Haematol 4(4):355\u2013374. https:\/\/doi.org\/10.1111\/j.1365-2141.1958.tb06038.x","journal-title":"Br J Haematol"},{"key":"6407_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.critrevonc.2018.01.011","volume":"123","author":"A Paix","year":"2018","unstructured":"Paix A, Antoni D, Waissi W, Ledoux MP, Bilger K, Fornecker L et al (2018) Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review. Crit Rev Oncol Hematol 123:138\u2013148. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.01.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"6407_CR36","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J et al (2024) Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett 605:217264","journal-title":"Cancer Lett"},{"issue":"4","key":"6407_CR37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jtct.2020.12.013","volume":"27","author":"S Mizuno","year":"2021","unstructured":"Mizuno S, Takami A, Kawamura K, Arai Y, Kondo T, Kawata T et al (2021) Allogeneic hematopoietic cell transplantation for adolescent and young adult patients with acute myeloid leukemia. Transpl Cell Ther 27(4):314.e311-314.e310","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"6407_CR38","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2020.02.025","volume":"26","author":"M Hamadani","year":"2020","unstructured":"Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A et al (2020) Higher total body irradiation dose intensity in Fludarabine\/TBI-Based Reduced-Intensity conditioning regimen is associated with inferior survival in Non-Hodgkin lymphoma patients undergoing allogeneic transplantation. Biol Blood Marrow Transpl 26(6):1099\u20131105. https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.025","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"6407_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bmt.2015.238","volume":"51","author":"S Ben-Barouch","year":"2016","unstructured":"Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R (2016) Busulfan fludarabine vs Busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transpl 51(2):232\u2013240. https:\/\/doi.org\/10.1038\/bmt.2015.238","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"6407_CR40","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.bbmt.2018.03.011","volume":"24","author":"M Gooptu","year":"2018","unstructured":"Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P et al (2018) A comparison of the myeloablative conditioning regimen Fludarabine\/Busulfan with cyclophosphamide\/total body irradiation, for allogeneic stem cell transplantation in the modern era: A cohort analysis. Biol Blood Marrow Transpl 24(8):1733\u20131740. https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"6407_CR41","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1046\/j.1365-2141.2001.03044.x","volume":"114","author":"US Schuler","year":"2001","unstructured":"Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R et al (2001) Intravenous Busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 114(4):944\u2013950. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03044.x","journal-title":"Br J Haematol"},{"issue":"12","key":"6407_CR42","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/s41409-019-0579-0","volume":"54","author":"T Ruutu","year":"2019","unstructured":"Ruutu T, van der Werf S, van Biezen A, Backman JT, Peczynski C, Kr\u00f6ger N et al (2019) Use of Busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the transplant complications working party of the EBMT. Bone Marrow Transplant 54(12):2013\u20132019. https:\/\/doi.org\/10.1038\/s41409-019-0579-0","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6407_CR43","first-page":"736","volume":"49","author":"RL Heideman","year":"1989","unstructured":"Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ et al (1989) Phase I and Pharmacokinetic evaluation of Thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of Thiotepa. Cancer Res 49(3):736\u2013741","journal-title":"Cancer Res"},{"issue":"7","key":"6407_CR44","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41375-023-01924-x","volume":"37","author":"P Berning","year":"2023","unstructured":"Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F et al (2023) Allogeneic hematopoietic stem cell transplantation for NK\/T-cell lymphoma: an international collaborative analysis. Leukemia 37(7):1511\u20131520. https:\/\/doi.org\/10.1038\/s41375-023-01924-x","journal-title":"Leukemia"},{"issue":"13","key":"6407_CR45","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1097\/CM9.0000000000001575","volume":"134","author":"ZY Gu","year":"2021","unstructured":"Gu ZY, Dong YJ, Fu XR, Li NN, Liu Y, Wu XX et al (2021) A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. Chin Med J (Engl) 134(13):1584\u20131592. https:\/\/doi.org\/10.1097\/cm9.0000000000001575","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"6407_CR46","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1016\/j.bbmt.2019.12.499","volume":"26","author":"A Salhotra","year":"2020","unstructured":"Salhotra A, Nikolaenko L, Chen L, Tsai N-C, Smith DL, Nademanee A et al (2020) Long term outcomes of patients with aggressive T-Cell Non-Hodgkin lymphoma undergoing allogeneic stem cell transplantation: retrospective results from single center. Biol Blood Marrow Transplant 26(3):S249. https:\/\/doi.org\/10.1016\/j.bbmt.2019.12.499","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"6407_CR47","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ejh.13465","volume":"105","author":"G McIlroy","year":"2020","unstructured":"McIlroy G, Barmayehvar B, Kamarajah SK, George L, Gondal AZ, Malladi R, Chaganti S (2020) Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive T-cell lymphoma. Eur J Haematol 105(4):514\u2013516. https:\/\/doi.org\/10.1111\/ejh.13465","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06407-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:54:56Z","timestamp":1757184896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06407-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6407"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06407-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Institute of Hematology & Blood Diseases (Approval Number: QTJC2024018-EC-1), and a waiver of informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}